Compare EXFY & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | AGEN |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 147.4M |
| IPO Year | 2021 | 1999 |
| Metric | EXFY | AGEN |
|---|---|---|
| Price | $1.89 | $3.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.50 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 2.4M | 904.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $142,101,000.00 | $42,877,086.00 |
| Revenue This Year | $0.42 | $107.63 |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | ★ N/A | $3.18 |
| Revenue Growth | 2.06 | ★ 89.95 |
| 52 Week Low | $0.69 | $2.71 |
| 52 Week High | $2.26 | $7.04 |
| Indicator | EXFY | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 51.47 |
| Support Level | $1.37 | $2.92 |
| Resistance Level | N/A | $3.41 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 85.04 | 58.33 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.